Fig. 2.

Treatment of CEA-expressing tumors in Ad5-immune mice. C57Bl/6 mice (n = 7 per group) were immunized two times at a 2-week interval with Ad5 [E1-]-null (no transgene insert). Two weeks following the final Ad5 [E1-]-null administration mice were inoculated with 10⁶ MC38-cea2 cells subcutaneously in the left flank and administered injection buffer (tumor controls), 10¹⁰ VP of Ad5 [E1-]-CEA or 10¹⁰ VP of Ad5 [E1-, E2b-]-CEA in the right flank on days 0, 7, and 14. Tumors were measured by two opposing dimensions (a, b) and volumes were calculated according to the formula V = (a × b)²/2. Error bars represent the standard deviation of tumor volume. Asterisk indicates days that the Ad5 [E1-]-CEA treated mice had significantly smaller tumors than control mice. Hat symbol indicates days that the Ad5 [E1-, E2b-]-CEA treated mice had significantly smaller tumors than control and Ad5 [E1-]-CEA treated mice